GO
Loading...

Seattle Genetics Inc

More

  • Better patient survival rates prompted Bristol-Myers Squibb to bring an early end to an advanced study of a potential treatment for one of the most common forms of lung cancer. Last month, the Food and Drug Administration granted accelerated approval to Opdivo as a treatment for a deadly form of skin cancer that cannot be removed by surgery and has spread...

  • Dec 6- Merck& Co Inc's drug that harnesses the immune system to fight cancer showed promise in Hodgkin lymphoma patients whose disease had progressed following prior therapies, according to data from a small, early stage trial being presented at a medical meeting. Craig Moskowitz, the study's principal investigator from Memorial Sloan Kettering Cancer...

  • Dec 6- Eighty-seven percent of Hodgkin lymphoma patients responded to a Bristol-Myers Squibb drug that helps the immune system fight the blood cancer, according to data from a small, early stage trial released on Saturday. Margaret Shipp, co-lead investigator of the Checkmate-039 study from Dana-Farber Cancer Institute in Boston. The results were being...

  • Sept 29- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Seattle Genetics said it expected to submit a marketing application to FDA for the drug's supplemental use in 2015..

  • Sept 29- Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body.

  • Cramer: Aggressive M&A signals undervalued shares Monday, 9 Jun 2014 | 6:06 PM ET

    After a string of mergers, Cramer thinks investors may be looking at significantly higher valuations in parts of the market.

  • Jim Cramer hit the road Wednesday to investigate the prospects of 4 firms headquartered in Seattle.

  • Midday movers: Crocs, Conversant, Lorillard & More Wednesday, 12 Feb 2014 | 12:06 PM ET

    Some of Wednesday's midday movers:

  • Cramer: These 'anointed' stocks will go higher Thursday, 12 Sep 2013 | 10:15 AM ET

    There are a handful of stocks out there that the market loves and should take even higher by the end of the year, CNBC's Jim Cramer said Thursday.

  • Cramer always notes superlatives in any stock. What does he think of this play now?

  • These biotech names are ripe for takeover: Cramer Tuesday, 27 Aug 2013 | 7:19 PM ET

    We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.

  • Cramer: Easy Money Over, Ring the Register Monday, 1 Jul 2013 | 6:25 PM ET

    The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.

  • Lightning Round: Dollar Tree, Toll Brothers & More Tuesday, 16 Apr 2013 | 6:43 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Cramer: Investing in Future of Cancer Drugs Thursday, 4 Apr 2013 | 6:28 PM ET

    At least three companies are on the cutting edge of new treatments for perhaps the most feared disease known to mankind.

  • 5 Stocks Poised to Pop on Bullish Earnings Monday, 11 Feb 2013 | 4:56 PM ET

    TheStreet.com suggests stocks that could pop on their earnings reports.

  • Biotech's a Buy, but Hold Off on HMOs: Fund Manager Wednesday, 9 Jan 2013 | 2:02 PM ET

    Rock bottom interest rates will likely boost key stocks in the biotechnology sector, but Obamacare will dampen prospects for HMO shares.

  • 13 Biotech Stock Predictions for 2013 Wednesday, 2 Jan 2013 | 7:55 AM ET

    TheStreet.com offers up 13 biotech predictions for 2013.

  • Seattle Genetics expands collaboration with Abbott Tuesday, 23 Oct 2012 | 12:10 AM ET

    BOTHELL, Wash.-- Seattle Genetics Inc. said Tuesday that pharmaceutical giant Abbott Laboratories has agreed to pay $25 million plus potential milestone payments for the biotech firm's experimental antibodies to fight cancer.

  • Cramer Interviews Seattle Genetics CEO Tuesday, 5 Jun 2012 | 6:50 PM ET

    The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.

  • 7 Cancer Drug Stocks to Know Right Now Wednesday, 14 Mar 2012 | 2:39 PM ET
    Three laboratory technicians using microscope

    Savvy investors know that making money on the “ASCO trade” means getting in early as cancer drug stocks typically trade up into the closely watched medical meeting.